See the DrugPatentWatch profile for exparel
Hengrui Medicine has not announced a specific generic launch date for Exparel in 2024. However, the patent exclusivity for Exparel is set to expire in the coming years, which will pave the way for generic competition.
When does Exparel's patent exclusivity end?
Exparel, developed by Pacira BioSciences, holds patent protection that is expected to expire in the near future, according to DrugPatentWatch.com. The exact expiry date can be influenced by various factors, including ongoing patent litigation and regulatory approvals.
What is Exparel and what is it used for?
Exparel is a non-opioid injectable medication used to manage post-surgical pain. It utilizes DepoFoam technology, which allows for the extended release of the anesthetic bupivacaine, providing pain relief for up to 72 hours after a single administration.
How does Exparel work to manage pain?
Exparel works by releasing bupivacaine slowly over time. After injection into the surgical site, the DepoFoam particles gradually break down, delivering the anesthetic directly to the nerves in the area. This sustained release mechanism targets pain at its source, reducing the need for opioid pain relievers.
What are the benefits of using Exparel for pain management?
Exparel offers a non-opioid alternative for post-operative pain control, which can help mitigate the risks associated with opioid use, such as addiction, respiratory depression, and constipation. Its extended duration of action means patients can experience prolonged pain relief from a single dose, potentially leading to fewer complications and improved recovery.
Who are Exparel's main competitors?
While Exparel is a novel formulation, other pain management strategies and drugs compete for market share. These include traditional local anesthetics, opioid analgesics, and other non-opioid pain relievers. The advent of generic Exparel will introduce direct competition.
What are the potential risks and side effects of Exparel?
Common side effects of Exparel include nausea, constipation, headache, and vomiting. As with any injectable medication, there is a risk of infection at the injection site. More serious side effects, though rare, can include nerve injury or a severe allergic reaction. Patients should discuss potential risks with their healthcare provider.
What is the status of generic Exparel development?
Several pharmaceutical companies, including Hengrui Medicine, are likely developing generic versions of Exparel. The launch of these generics is contingent upon the expiration of Exparel's patents and successful approval by regulatory agencies.
What happens after Exparel's patents expire?
Following the expiration of Exparel's patents, generic manufacturers will be able to market their own versions of the drug. This is expected to increase competition, potentially leading to lower prices for the medication and broader patient access.
Where can I find more information on Exparel patents?
Information regarding Exparel's patent status and expiry can be found on resources like DrugPatentWatch.com, which tracks patent information for various pharmaceuticals.
Sources:
1. https://drugpatentwatch.com/